ArticleJournal of orthopaedic surgery and research2025
AP39 suppresses osteoclast differentiation and neural factor expression under inflammatory condition.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeChronic pain is the major complaint of most Rheumatoid arthritis (RA) patients, which still lacks fully understanding and effective management. This study aims to establish a connection of RA pain with osteoclast activity and validate the effect of AP39 as a potential therapeutic agent.
methodsSynovial tissue from RA patients were employed with histological and immunofluorescent assay to determine the inflammatory and innervation status. CCK8 assay and TRAP staining were conducted to verify the effect of AP39 on osteoclast differentiation. The expression of axon guidance factors was then determined by qPCR and WB assay.
resultsHematoxylin and Eosin (HE) staining and immunofluorescence presented a hyper-inflammation status and increased nerve distribution on RA synovial membrane. And the CCK8 assay and TRAP staining indicated 20 µM of AP39 inhibited LPS-stimulated osteoclast differentiation without cytotoxicity. qPCR assay and Western blot analyses validated AP39 suppressed genes and proteins expression of axon guidance factors on osteoclast after LPS stimulation.
conclusionsOur study validates a hyper-inflammation and hyper-innervation status in the synovial membrane of RA patients, which may be related to the exaggerated inflammatory osteoclast activity. Additionally, we proved that AP39 may serve as a therapeutic agent for suppressing the cellular differentiation and axon guidance factors expression of osteoclast under inflammatory circumstance, thereby indicating AP39 a potential option for RA management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.